CD19 and diffuse large B-cell lymphoma: Tisagenlecleucel is a CD19-directed chimeric antigen receptor (CAR)-T cell therapy approved for use in adult patients with r/r DLBCL following two or more lines of prior therapy based on results from the pivotal JULIET trial (3, 4).